Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021
Topline readout of Group 2 active disease anticipated in Q1 2022
Company to host year-end conference call and webcast in Q1 2022
PR Newswire
HOUSTON, Nov. 10, 2021